TickerTalks
Browse all tickers →
TickerTalks›$NUTX
NUNUTX

Nutex Health, Inc.

$NUTX·$1.4B·Medical - Care Facilities·Healthcare
$187.42+0.3%1Y+68.6%
Mentions · last 7 days
2026-08-07: 2 posts2026-08-08: 1 posts2026-08-09: 0 posts2026-08-10: 12 posts2026-08-11: 27 posts2026-08-12: 1 posts2026-08-13: 5 posts48+2%
Price updated 7h ago·X counts updated 1d ago
NUNUTX
$NUTXNutex Health, Inc.
$187.42+0.33%48 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NUTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-08-13

The move is getting stronger, with heavier trading behind it.

Nutex is either a No-Surprises-Act arbitrage machine or a regulatory-window that closes — the earnings beat is real; the durability isn't

Nutex operates micro-hospitals (21 facilities) and a physician-network JV structure whose margins depend heavily on out-of-network arbitration outcomes under the No Surprises Act.

  • Q2 EPS $9.58 vs $4.95 estimate — an 89% beat; Q1 was $6.70 vs $3.99 (63% beat); operating margin 57.8% for a hospital operator is atypical.
  • 2026 consensus EPS $21.52, 2027 $23.03 — Street is modeling the arbitration windfall as durable.
  • Trailing P/E 7.5x, EV/EBITDA 3.8x, 20% FCF yield — cheap on multiples if you believe the earnings; expensive if you don't.
  • Tiny 3.4M float with beta 1.99 — thin liquidity + high beta amplifies both directions.
  • Position 75% into 52-week range, +27% above 200-day MA — momentum is on, but not extended.

Upside is continued facility ramp and stable arbitration outcomes; downside is a regulatory or judicial narrowing of NSA arbitration economics that resets margins.

What to watch: Any CMS or judicial update to No Surprises Act arbitration mechanics and Q3 print (Nov 17) for margin durability.

On the calendar: 2026-11-17

regulatory dependencythin float

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠5 posts analyzed · as of 2026-08-14 · top-engagement diverged

Nutex Health chatter is mixed. Bulls call it a real-estate + healthcare + AI play with conviction to double or triple on new-CEO catalyst; adding on drops to $153-$163.50. Bears cite the 30%+ EBITDA margins as gaming the No Surprises Act IDR process (85%+ arbitration wins) with regulatory risk. 14-month rectangle base with $193 flip-to-support setup.

Read the AI verdict + X sentiment for $NUTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Healthcare company developing and operating micro-hospital and freestanding emergency room facilities alongside a population health management platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $NUTX.

Medical - Care Facilities · Healthcare

No material change from last week — hospital systems continue to rely on travel nursing and locum physician staffing to fill permanent workforce gaps that training pipelines cannot replenish at..

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.6%YTD
+29.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
7.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
33.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
43.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
20.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
48.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
51.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$9.38$4.95+89.5%
Q1 2026Apr 30, 2026$6.52$3.99+63.4%
Q4 2025Mar 5, 2026$1.61$5.56-71.0%
Q3 2025Nov 19, 2025$7.76$1.81+328.7%
Next earningsTue, Nov 17·consensus EPS $5.26

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$210.8M-13.6%67.0%57.8%$9.58$31.7M
Q1 FY26$216.5M+2.2%42.4%37.5%$6.70$74.3M
Q4 FY25$151.7M-41.1%30.4%20.4%$1.68$69.0M
Q3 FY25$267.8M+239.9%57.8%48.7%$8.27$99.2M

Forward consensus

2-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$880.4M$869.2M – $900.8M$21.52$21.16 – $22.173
FY27$969.2M$956.9M – $991.7M$23.03$22.65 – $23.723

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 3.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.995-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMar 20Frank E JaumotDirector150 sh$14KBuyMar 19Warren HosseinionPresident252 sh$24KBuyMar 17Kelvin SpearsDirector10 sh$945BuyMar 13Pamela W. MontgomeryChief Legal Officer-Healthcare79 sh$7K
+ 30 other (17 exempts · 6 inkinds · 4 awards · 3 others) in window

See when $NUTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 218-K — Item 1.01: Material agreement
AI summary

Nutex Health (NUTX) filed an 8-K on July 22, 2026 (event date July 15) under Item 1.01, announcing a material definitive agreement. The excerpt is the cover page; the counterparty and agreement terms are in the body. Nutex Health operates micro-hospitals and hospital-based physician practices; material agreements often relate to new facility development, physician group acquisitions, or financing arrangements.

8-KShareholder voteApr 238-K — Item 5.07: Shareholder vote
+ 14 other (3 earnings 8-Ks · 3 13Gs · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)seekingalpha.com·3d agoNutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcriptseekingalpha.com·7d agoNutex Health Q2 Earnings Call Highlightsmarketbeat.com·8d agoNUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSprnewswire.com·8d agoNutex Health Schedules 2026 Second Quarter Financial Results Release and Conference Callprnewswire.com·25d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$STLN$AVAH$THC$PIII$DVA$AMN$HCA$PACS
Voices on X · top 5 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport